

New Advances in JAK Inhibitors and non-JAK Inhibitors in Myelofibrosis: Updates from ASH 2023

References

1. Mascarenhas JO, Verstovsek S. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. *Cancer*. 2022 Jul 15;128(14):2717-2727.
2. Ajufo H, Bewersdorf JP, Harrison CN, et al. Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
3. Vachhani P, Yacoub A, Traer E, et al. Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies. *Blood*. 2023;142(Suppl 1):4554.
4. Mesa RA, Perkins AC, Goh YT, et al. Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naïve or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
5. Rampal R, Grosicki S, Chraniuk D, et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, Phase 3 study. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
6. Onclive. Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study. December 19, 2023. <https://www.onclive.com/view/pelabresib-in-combination-with-ruxolitinib-for-janus-kinase-inhibitor-treatment-na-ve-patients-with-myelofibrosis-results-of-the-manifest-2-randomized-double-blind-phase-3-study>. Accessed January 16, 2024.
7. Pemmaraju N, Mead AJ, Somerville TCP, et al. Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
8. Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *Am J Hematol*. 2020 Jun;95(6):594-603.
9. Gupta V, Yacoub A, Verstovsek S, et al. Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial. *Blood*. 2022;140(Suppl 1):3935-3937.
10. Harrison CN, Mesa RN, Talpaz M, et al. Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
11. Tantravahi SK, Kishtagari A, Maher K, et al. Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification. Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.

12. Scandura JM, Gerds AT, Ritchie EK, et al. A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044). Presented at: 65th ASH Annual Meeting and Exposition, December 9-12, 2023. San Diego, California.
13. Maher K, Rampal RK, Bose P, et al. A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034). *Blood*. 2023;142(Suppl 1):3209.

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Karyopharm Therapeutics.